| 2008-05-31: |
Erbitux Significantly Prolongs Survival in 1st - Line Treatment of Non - Small Cell Lung Cancer
Chicago and Darmstadt, Germany ( PRN/ots ) - - New Data Provides the Basis for the Future Role of Erbitux ( cetuximab ) as a Standard in Combination With Platinum - Based Chemotherapy in the 1st - Line Treatment of Patients With Non - Small Cell Lung Cancer ( NSCLC ) - Location: (...) |
| 2008-11-13: |
Avastin( R ) Gives an Additional 4 Months of Life to Patients With one of the Most Common Types of Lung Cancer
Basel, Switzerland, November 13 ( PRN/ots ) - - Phase III Trial Shows Patients With Advanced Adenocarcinoma of the Lung Have a 45 Prozent Better Chance of Survival With Avastin Roche announced today that an exploratory analysis of the pivotal phase III E4599 study demonstrated (...) |
| 2007-09-19: |
New Data Confirm Clear Benefit of Protelos( R ) ( Strontium Ranelate ) in the Treatment of Postmenopausal Osteoporosis
Honolulu, Hawaii ( PRN/ots ) - - Protelos( R ) Relaunches Bone Formation and Increases Bone Volume in Patients on Long Term Bisphosphonate Treatment Protelos( R ) ( strontium ranelate ) stimulates bone formation and increases bone volume by 30 Prozent in high fracture risk patients who have been on long term (...) |
| 2006-08-02: |
Medify Solutions Limited ( Pink Sheets MFYS ) Explains the Sales Potential for UK Remote Access Market
Gateshead, England ( PRN/ots ) - On the 1st September 2006, Medify Solutions Limited will roll out its 'remote access to patient notes' product, MedifyRemote, to its National Health Service ( NHS ) customers. The first NHS site, as published previously , will be in Doncaster in the (...) |
| 2010-03-09: |
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
ABBOTT PARK, Illinois and REDWOOD CITY, California, March 9, 2010 ( PRN/ots ) - - Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early - and mid - stage pharmaceutical pipeline. Abbott will acquire Facet for US$27 per share in (...) |
| 2007-09-05: |
Pieris validates the use of Anticalins® as ophthalmologic biotherapeutics
Freising - Weihenstephan, Germany ( na Originaltextservice ) - Pieris AG, a bio - pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced successful completion of a series of preclinical studies validating the use of Anticalins® in ophthalmologic disease. The (...) |
| 2006-12-15: |
Imminent Arrival of Latest HIV Drug Darunavir, When Combined With FUZEON, Will Give Treatment - Experienced Patients a Better Chance to Achieve Undetectable Viral Load
Basel, Switzerland ( PRN/ots ) - Today's positive opinion by the European Committee for Medicinal Products for Human Use ( CHMP ) of Tibotec's boosted protease inhibitor darunavir is good news for HIV treatment - experienced patients facing drug resistance. Studies have shown that darunavir, when used in combination (...) |
| 2009-03-26: |
The Naked Truth Revealed: World Class Photographic Exhibit Captures the Reality Behind Living with Psoriasis
Amsterdam ( PRN/ots ) - - Psoriasis Patients from Around the World Come together to Bare Their Skin and Share Their Stories for New Pan - European Educational Programme AMSTERDAM, March 26 /PRNewswire/ - - Psoriasis: The Naked Truth, a new pan - European educational programme to expose the (...) |
| 2006-12-14: |
Landmark Study of Avastin in Lung Cancer Published Today in New England Journal of Medicine
Basel, Switzerland ( PRN/ots ) - - Avastin is First Medicine to Extend Survival Beyond One Year in Patients With Previously Untreated Non - Small Cell Lung Cancer Avastin is the first medicine proven to help previously untreated patients suffering from the most common form (...) |
| 2010-05-03: |
BIO 2010: German Molecular Diagnostics Segment Posting Double - Digit Growth
Berlin/Chicago ( na Originaltextservice ) - Molecular diagnostics has quickly become one of the most important biotechnology segments in Germany. With an estimated 10 percent share of the EUR 2 billion German diagnostics market, the segment enjoys a compound annual growth rate of (...) |
| 2007-01-18: |
GlaxoSmithKline Initiates Head - to - Head Study of Cervical Cancer Vaccines
Philadelphia, Pennsylvania ( PRN/ots ) - - Study to Compare Immunogencity of GSK's Cervical Cancer Candidate Vaccine, CERVARIX( R ), to Merck's Gardasil( R ) GlaxoSmithKline ( NYSE: GSK ) announced today the initiation of the first study of its kind designed to compare the immunogenicity of its cervical cancer candidate (...) |
| 2009-06-23: |
New Educational Initiative Urges People With Rheumatoid Arthritis ( RA ) to Dedicate One Day so That They May Make a Lasting Difference to How They Live With Their Condition
Maidenhead, England ( PRN/ots ) - - My Day for RA Launches Across Europe Today: A Novel 'Goal - Centred' Patient Programme Recognising that rheumatoid arthritis ( RA ) can cause deformity, disability and loss of independence without effective management - My Day for RA, a new educational programme, (...) |
| 2007-03-08: |
Roche Launches AnaemiaWorld.com in Recognition of World Kidney Day
Basel, Switzerland ( PRN/ots ) - - New global educational resources spotlight renal anaemia, a common under - recognized complication of Chronic Kidney Disease To help support health professionals who play a key role in educating and managing patients with Chronic Kidney Disease ( CKD ), Roche today (...) |
| 2006-01-03: |
AstraZeneca Submits sNDA for SEROQUEL( R ) for Bipolar Depression Treatment
Alderley Park, England ( PRN/ots ) - - Filing Seeks Approval of SEROQUEL as a Monotherapy Treatment for Bipolar Depression AstraZeneca today announced submission of a supplemental New Drug Application ( sNDA ) to the US Food and Drug Administration ( FDA ) to seek approval for a new (...) |
| 2006-07-25: |
Remote Delivery Group Medify International Springboards Into European Healthcare
Toronto ( PRN/ots ) - Remote technology company Medify International announced today that it is building on its UK collaboration with Oracle, the world's largest enterprise software company, and expanding across Europe. Following the success of its collaborative approach with Oracle in delivering a tried and (...) |
| 2004-12-15: |
Historic Breast Cancer Awareness Initiative Meets Global Need for Breast Cancer Information
London ( PRN/ots ) - - 'Redefining Hope and Beauty' Campaign Surpasses All Expectations Breast cancer charities from around the world are today celebrating the success of the world's first truly global breast cancer awareness campaign - 'Redefining Hope and Beauty'. In the first few weeks (...) |
| 2006-07-28: |
In the Interests of Patients, Roche Will Consider all Options Following CHMP Opinion on Tarceva in Pancreatic Cancer
Basel, Switzerland ( PRN/ots ) - Roche announced today that its cancer medicine Tarceva ( erlotinib ) has received a negative opinion from the European Committee for Medicinal Products for Human Use ( CHMP ) for use in combination with gemcitabine chemotherapy for the first line treatment of advanced pancreatic (...) |
| 2009-04-20: |
Newly Published Study Shows That Re - Treatment With Pegasys( R ) ( Peginterferon Alfa - 2a ) Provides Hepatitis C Patients With a Second Chance for a Cure
Basel, Switzerland ( PRN/ots ) - New data published today in a major peer - reviewed journal, Annals of Internal Medicine, show that re - treatment with Pegasys( R ) ( peginterferon alfa - 2a ) plus Copegus( R ) ( ribavirin ) provides previously - treated hepatitis C patients a second chance for a cure. The study (...) |
| 2009-10-09: |
New Data From the PRESTA Trial Demonstrate the Benefit of Enbrel( R ) in Patients With Psoriasis and Psoriatic Arthritis
Maidenhead, England ( PRN/ots ) - - Data Presented at the 18th EADV Congress add to the Comprehensive Long - Term Data set as Enbrel Reaches Five - Year Anniversary in Treating Patients With Plaque Psoriasis in Europe Data signalling that Enbrel( R ) ( etanercept ) can improve the quality (...) |
| 2008-02-14: |
GenOdyssee Receives Notice of Allowance from U.S. Patent Office for Improved Interferon - Alpha Aimed at Hepatitis C
Paris ( PRN/ots ) - - GenOdyssee has Received Notice of Allowance of United States Patent Application Covering it's Lead HCV Interferon - Alpha Product GEA007.1, a Natural Protein With Improved Anti - HCV Genotype 1 Activity GenOdyssee S.A., a biotechnology company dedicated to the discovery and development (...) |
| 2009-09-02: |
Pitavastatin Demonstrates no Significant Drug - to - Drug Interaction When Administered With CYP3A4 Inhibitors
Barcelona, Spain ( PRN/ots ) - - Data Shows Potential Tolerability Advantage for Pitavastatin Compared With Other Statins New data presented at the European Society of Cardiology congress ( ESC ) demonstrated that the co - administration of the cytochrome inhibitor itraconazole has no clinically relevant effect on (...) |
| 2006-05-26: |
The Tempus International Awards for Lung Cancer Journalism
London ( PRN/ots ) - - The Global Lung Cancer Coalition ( GLCC ) is Excited to Launch the Tempus Journalism Awards, a Global Initiative to Recognise Excellence in Lung Cancer Reporting Lung cancer is the leading cause of cancer - related death in both men and women (...) |
| 2006-03-28: |
Soaring Cholesterol Levels Could Plunge Europe Into a Welfare Crisis by 2020 if not Tackled Today
Brussels ( PRN/ots ) - - Stockholm Network Report Says Crisis can be Averted by Better Practice Patterns and Newer Therapies A major new report by think tank, The Stockholm Network, shows policy makers are not doing enough to tackle rising cholesterol levels. The report (...) |
| 2004-12-01: |
Isotechnika Inc. receives No Objection Letter from Health Canada for Phase III Psoriasis Trial
Edmonton, Alberta ( PRN/ots ) - Isotechnika Inc. announced today that the Company received a No Objection Letter from Health Canada for the commencement of a Phase III trial for its lead immunosuppressive drug candidate, ISA247. The trial will be performed over a twenty - four (...) |
| 2006-06-16: |
Innovative Technology for Treatment of Renal Anaemia Unveiled Today
Basingstoke, England ( PRN/ots ) - - First Human Cell Line - Derived Erythropoietin Research Reported BASINGSTOKE, England, June 16 /PRNewswire/ - - - Abstract Numbers: 562 and 576 Effective treatment of anaemia in patients suffering from chronic kidney disease ( CKD )( x ) is possible with the first erythropoietin product (...) |
| 2009-09-30: |
Muscle and Joint Pain Costs European Economies up to EUR240 Billion a Year
Brussels ( PRN/ots ) - - New Study Reveals Musculoskeletal Disorders ( MSDS ) Responsible for More Sick Days Than any Other Health Condition A new study today finds that musculoskeletal disorders ( MSDs ) account for nearly half ( 49 Prozent ) of all absences from work and 60 Prozent of permanent (...) |
| 2009-09-25: |
Resverlogix Notice of Conference Call & Webcast to Discuss Clinical Trial Data
Calgary, Canada ( PRN/ots ) - Resverlogix Corp. ( TSX:RVX ) announced today that it will host a live teleconference and webcast on Tuesday, September 29, 2009 at 1:00 pm Eastern/11:00 am Mountain time. The purpose of the teleconference is to discuss the top (...) |
| 2005-06-17: |
Revolutionary Treatment Avastin Helps People with Advanced Colorectal Cancer Live Longer While Preserving Their Quality of Life
Barcelona, Spain ( PRN/ots ) - The addition of Avastin( R ) ( bevacizumab, rhuMAb - VEGF ) to chemotherapy increases the survival of patients with advanced colorectal cancer while also preserving their quality of life for longer according to new data presented today at the 7th World Congress on Gastrointestinal (...) |
| 2004-11-29: |
Bioreason Launches ClassPharmer( TM ) Suite Lite for Lead Optimization and Predictive Tox
Santa Fe, New Mexico, November 29 ( PRN/ots ) - Bioreason, Inc., announced today the release of ClassPharmer( TM ) Suite Lite, a new edition of the company's software system to increase success in the hits - to - leads - to - clinic process within drug discovery. ClassPharmer( TM ) Suite Lite is (...) |
| 2008-09-09: |
Fenofibrate Reduces the Risk of Amputations in Patients With Type 2 Diabetes
Rome ( PRN/ots ) - - Exciting New Data From the FIELD Study Show Additional Microvascular - Associated Benefits of Fenofibrate - The First Time in a Large - Scale Prospective Study That any Lipid - Modifying Therapy has Been Shown to Significantly Reduce the Risk of Lower - Limb (...) |
| 2011-04-06: |
joimax® - the 1st US TESSYS® User Meeting in Denver, Colorado, USA heralds 10 - year anniversary celebrations
Karlsruhe ( na Originaltextservice ) - At the same time joimax® Inc., the US subsidiary celebrates its fifth anniversary, exhibits at the AANS and for the first time awards the Parviz Kambin prize in the frame of the second international TESSYS® - User Meeting (...) |
| 2008-05-30: |
Tarceva( R ) Delivers Benefits Across Broad Range of NSCLC Patients - Confirmed by New Data
Chicago, Illinois ( PRN/ots ) - - Tarceva Extends Length and Quality of Life in Largest Non - Small Cell Lung Cancer ( NSCLC ) Phase IV Study Ever Conducted - For non - US and non - UK Media Only New data presented at ASCO 2008 from TRUST( 1 ), (...) |
| 2009-10-20: |
Excellence in Epilepsy Journalism Award
Brussels ( PRN/ots ) - - IBE and UCB Announce Winners of Award to Improve Understanding of Epilepsy Around the World The International Bureau of Epilepsy and UCB are pleased to announce the winners of the Excellence in Epilepsy Journalism Award 2009. To view the (...) |
| 2007-11-20: |
Review Publication Confirms the Benefits of Highly Effective Oral Cancer Drug Xeloda( R ) ( capecitabine ) Over Intravenous Chemotherapy in Advanced Breast Cancer
Basel, Switzerland, November 20 ( PRN/ots ) - - Annals of Oncology Paper Suggests That Oral Agents Such as Xeloda, Which are Proven to be Equally Effective and Have a Tolerable Side Effect Profile, Should Replace Traditional Intravenous Chemotherapy A review paper in Annals of (...) |
| 2006-10-05: |
Isotechnika Reports Final Safety and Efficacy Data From Phase III Psoriasis Extension Trial
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. ( TSX:ISA ) reports final safety and efficacy data subsequent to 60 weeks of continuous treatment with ISA247. All safety and efficacy endpoints were met. Patients completing the 24 week Canadian Phase III SPIRIT trial were given the opportunity (...) |
| 2005-07-25: |
Sanofi Pasteur Begins Shipping Adacel( TM ) Vaccine in the US for Combined Protection Against Tetanus, Diphtheria, and Pertussis
Swiftwater, Pennsylvania and Lyon, France ( PRN/ots ) - - First and Only Booster in the US for Protection Against Pertussis From Adolescence Through Adulthood Sanofi Pasteur, the vaccines business of the sanofi - aventis Group ( EURONEXT: SAN ), ( NYSE: SNY ), announces the availability of Adacel( TM ) ( Tetanus (...) |
| 2007-01-30: |
Perceptronix Collaborates With BC Cancer Agency on Early Oral Cancer Detection Project
Vancouver, Canada ( PRN/ots ) - Perceptronix Medical Inc. ( "Perceptronix" ) today announced its participation in a research project to detect early oral cancer lesions through a new initiative inside the BC Oral Cancer Prevention Program. This Program is bringing together a network of dentists, researchers and (...) |
| 2009-06-23: |
Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
Huntington Beach, California and Amsterdam ( PRN/ots ) - - International Expert Panel Recommends Use of Multigene Profiling Assays and Finds Intermediate Scores Lack Clinical Utility Agendia, a world leader in molecular cancer diagnostics, today announced the inclusion of its breast cancer recurrence test MammaPrint (...) |
| 2006-11-17: |
Women With Early Breast Cancer are More Likely to Remain Cancer Free by Changing Treatment From Tamoxifen to Arimidex( TM ) ( Anastrozole )
Macclesfield, England, November 17 ( PRN/ots ) - FOR INTERNATIONAL JOURNALISTS - NOT FOR US MEDIA - Data Published in the Lancet Oncology Report That Patients are More Likely to Live Cancer Free for Longer if Tamoxifen is Replaced With ARIMIDEXT( TM ) According to data published (...) |
| 2010-03-09: |
The Pediatric Dengue Vaccine Initiative Introduces www.DengueWatch.org - a News hub for Tracking Dengue Fever Epidemics Worldwide
Seoul, March 9, 2010 ( PRN/ots ) - PDVI ( Pediatric Dengue Vaccine Initiative ), a program of the International Vaccine Institute ( IVI ) funded by the Bill & Melinda Gates Foundation, announces today the launch of http://www.denguewatch.org, a news hub for tracking dengue fever epidemics worldwide. Breaking (...) |
| 2006-09-14: |
MacroChem Retains The Investor Relations Group
Wellesley Hills, Massachusetts ( PRN/ots ) - MacroChem Corporation ( OTC Bulletin Board: MACM ), a specialty pharmaceutical company that develops and seeks to commercialize pharmaceutical products based on proprietary drug delivery technologies, has retained The Investor Relations Group, Inc. ( IRG ), a full - service investor relations firm, (...) |
| 2008-01-11: |
cbm Responds to the Humanitarian Crisis in Kenya
Nairobi ( PRN/ots ) - cbm through its staff and Regional Office in Nairobi is providing emergency assistance to the humanitarian crisis in Kenya. It is estimated that around 500,000 people have lost their homes, due to the widespread violence following the disputed election. Prof. (...) |
| 2005-10-22: |
Head to Head Study Confirms Atypical Antipsychotic Efficacy Equivalence
Amsterdam, The Netherlands ( PRN/ots ) - - New data also demonstrate SEROQUEL tolerability benefits versus other atypicals in schizophrenia and reinforce therapeutic potential in bipolar disorder Seroquel ( quetiapine ), olanzapine and risperidone are equally effective in patients experiencing first episode psychosis, according to data presented today (...) |
| 2004-11-17: |
At the United Nations, Canada's Minister of Health and Mr. Ted Turner Launch a Public Health Early Warning Platform Driven by a Quebec Company
Montreal, November 17 ( PRN/ots ) - - Exceptional exposure for Nstein Technologies Nstein Technologies Inc. ( TSX - V: EIN ), an emerging leader in new Business Intelligence ( BI ) solutions, received international exposure today at the United Nations at the official launch of the enhanced version of (...)
- The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. - Any and all statement that may be prospective shall not be interpreted as such.
ots Originaltext: Nstein Technologies Inc. Im Internet recherchierbar: http://www.presseportal.de Contact: For further information: Nstein Technologies Inc.: Investor Relations: Bruno Martel, Finance Director, Nstein Technologies Inc., +1 - 514 - 908 - 5406, ext. 235, bruno.martel@nstein.com; François Kalos, The Equicom Group Inc., +1 - 514 - 844 - 6054, fkalos@equicomgroup.com; Media: Rina Marchand, Nstein Technologies Inc., +1 - 514 - 908 - 5406, ext. 294, rina.marchand@nstein.com |
| 2007-02-14: |
Sanofi pasteur to License Single Dose Japanese Encephalitis Vaccine From Acambis
Lyon, France ( PRN/ots ) - - New Vaccine Will Help Improve Public Health in Japanese Encephalitis Endemic Countries Sanofi pasteur, the vaccines business of the sanofi - aventis Group, announced today it has entered into an agreement with Acambis plc to license a single dose (...) |
| 2007-09-23: |
New Global Survey Highlights Deep Psychological Impact of Breast Cancer Recurrence on Both Patients and Physicians
Barcelona ( PRN/ots ) - - For Medical and Healthcare Media Only - FOR INTERNATIONAL JOURNALISTS - NOT FOR US MEDIA - Data Highlight the Need for More Positive Conversations Through Better Communication, Training and Use of Effective Treatments A devastating moment for a woman undergoing (...) |
| 2008-12-13: |
Agendia's Breast Cancer Test MammaPrint( R ) Identifies New Subset of Low Risk HER2+ Patients
Huntington Beach, California and Amsterdam ( PRN/ots ) - - - Recent Study Reveals Substantial Group of Traditionally Miscategorized HER2+ Patients Dr. Michael Knauer from the Netherlands Cancer Institute today announced data uncovering a substantial group of traditionally miscategorized low risk HER2+ patients. Agendia's highly accurate breast (...) |
| 2007-03-30: |
Xeloda Approved in Europe for the Treatment of Advanced Stomach Cancer
Basel, Switzerland ( PRN/ots ) - - New Oral Treatment Option Reduces Time in Hospital by 80 Prozent - For Non - US Media Only The European Commission has approved Xeloda in combination with platinum - based chemotherapy, for first - line use in patients with advanced stomach cancer. (...) |
| 2010-12-16: |
Researchers Confirm Omega - 3 EPA Required for Antidepressant Benefits
Dartmouth, Canada ( PRN/ots ) - Researchers at the University of Illinois at Chicago completed a review of previously published research on antidepressant benefits of Omega - 3 essential fatty acids eicosapentaenoic acid ( EPA ) and docosahexaenoic acid ( DHA ). The review comprised a meta - analysis of 15 randomized, double - (...) |
|
| back...
1
2
3
4
5
6
7
8
9
10
11
more... |
